YaleNewHaven**Health** Smilow Cancer Hospital

# **Grand Rounds**

### Friday, March 15, 9:00am

Microenvironmental Determinants of Systemic Therapy Response in Kidney Cancer: from human to mouse and back

#### featuring

## A. Ari Hakimi, MD

Associate Professor; Co-Leader, Translational Kidney Cancer Program, Memorial Sloan Kettering Cancer Center

#### 55 Park Street Auditorium I Zoom Access Continental breakfast will be available

Needs: There is a need for novel RCC biomarkers, RCC models, and novel immunotherapies to treat RCC.

Objectives: Understand new immunocompetent RCC models, novel treatment strategies, and biomarkers for RCC immune response.





## A Comprehensive Cancer Center Designated by the National Cancer Institute



Dr. Hakimi is a urologic surgeon whose focus is on the care of patients with urologic malignancies, especially kidney tumors. He received his medical degree from Albert Einstein College of Medicine and completed fellowship at Memorial Sloan Kettering Cancer Center.

His research aims to understand immune infiltration, inflammation, and the tumor microenvironment in RCC to identify novel therapeutic targets to overcome resistance to systemic therapies. These studies apply bulk, single-cell and spatial RNA sequencing, flow cytometry, and immunogenomic analyses to both patient samples and novel, immunocompetent kidney cancer mouse lines that his lab has developed.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine esignates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>®</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Ahmed- none. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.